News

/News

Poseida Therapeutics, Inc. Announces Worldwide License Agreement with Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies

San Diego, CA, August 11, 2015 – Poseida Therapeutics, Inc. (Poseida), a private biotechnology company spun out of Transposagen Biopharmaceuticals, Inc. (Transposagen), and headquartered in San Diego, CA, today announced they have entered into a worldwide License Agreement with Janssen Biotech, Inc. (Janssen) to research, develop, manufacture and commercialize licensed products using Janssen Centyrin technology.

Centyrins […]

By |August 11th, 2015|News|Comments Off on Poseida Therapeutics, Inc. Announces Worldwide License Agreement with Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies

Poseida Therapeutics, Inc., Expands Board of Directors

San Diego, CA, August 5, 2015 — Poseida Therapeutics, Inc. (Poseida), a privately-held human therapeutics spinout of Transposagen Biopharmaceuticals, Inc. (Transposagen), announces the appointment of Lars Ekman, M.D., Ph.D. and Nishan de Silva, M.D. to the Company’s Board of Directors.  Dr. Ekman joins the Board as the Company’s Chairman, and Dr. de Silva is appointed President.

“We are […]

By |August 5th, 2015|News|Comments Off on Poseida Therapeutics, Inc., Expands Board of Directors

Poseida Therapeutics to Participate in Jefferies 2015 Healthcare Conference

San Diego, CA, June 1, 2015 — Poseida Therapeutics, Inc. (“Poseida”), a privately-held human therapeutics spinout of Transposagen Biopharmaceuticals, Inc. (“Transposagen”), announces that company executives are scheduled to participate in the upcoming Jefferies 2015 Healthcare Conference in New York. The Company’s presentation will be on Monday, June 1 at 3:00 pm Eastern time. Eric Ostertag, M.D. Ph.D., Poseida’s CEO, […]

By |June 1st, 2015|News|0 Comments

Poseida Therapeutics, Inc., Expands into JLABS to Foster Research Collaboration with Janssen for Development of Allogeneic CAR-T Therapies

San Diego, CA, May 28th, 2015 — Poseida Therapeutics, Inc. (“Poseida”), a privately-held human therapeutics spinout of Transposagen Biopharmaceuticals, Inc. (“Transposagen”), has announced it has begun drug development operations at its new location at JLABS in San Diego, California.

The drug development and license agreement between Transposagen and Janssen, which was announced in November of 2014, has been transferred to […]

By |May 28th, 2015|News|0 Comments